{"entity":{"id":"mc-non-cleavable","kind":"term","name":"Maleimidocaproyl (mc), non-cleavable","aka":["mc-MMAF"],"tldr":"The non-cleavable maleimidocaproyl (mc) linker is a tether with no cleavage site: the payload is released only when the antibody is fully digested.","summary":"The non-cleavable maleimidocaproyl (mc) linker is a plain tether with no cleavage site, so its payload is released only when the antibody is fully digested. Such linkers rely on lysosomal proteolysis of the antibody and release a cysteine-linker-payload adduct rather than the free drug. Paired with MMAF in the form known as mafodotin, or mc-MMAF, the released species is charged and stays in the cell, trading the bystander effect for stability and a different toxicity profile. The linker belongs to the Antibody-drug conjugate (ADC) technology and the Linker (ADC) term, is matched with the payload MMAF, and is referenced by the drug record for Belantamab mafodotin.","asOf":"2026-09-09","wikipedia":"https://en.wikipedia.org/wiki/Trastuzumab_emtansine","links":[{"label":"mcMMAF non-cleavable linker (Doronina et al., Bioconjugate Chem 2006)","url":"https://doi.org/10.1021/bc0502917"}],"tags":[],"related":["mmaf"],"cancers":[],"sections":[],"technologies":["adc"],"targets":[],"drugs":["belantamab-mafodotin"],"companies":[],"institutions":[],"pathways":[],"terms":["linker"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":["paper-doronina-bioconjug-chem"],"journals":[],"dependsOn":[],"notes":[],"category":"ADC chemistry"},"route":"/terms/mc-non-cleavable/","neighbours":{"term":[{"id":"linker","kind":"term","name":"Linker (ADC)","route":"/terms/linker/"},{"id":"mmaf","kind":"term","name":"MMAF","route":"/terms/mmaf/"}],"technology":[{"id":"adc","kind":"technology","name":"Antibody-drug conjugate (ADC)","route":"/technologies/adc/"}],"drug":[{"id":"belantamab-mafodotin","kind":"drug","name":"Belantamab mafodotin","route":"/drugs/belantamab-mafodotin/"}],"paper":[{"id":"paper-doronina-bioconjug-chem","kind":"paper","name":"Enhanced activity of monomethylauristatin F through monoclonal antibody delivery: effects of linker technology on efficacy and toxicity","route":"/key-papers/paper-doronina-bioconjug-chem/"}]}}